Literature DB >> 11121232

Expression of the protein product of the PCPH proto-oncogene in human tumor cell lines.

A Rouzaut1, J A Recio, V Notario.   

Abstract

Expression of the Protein Product of the PCPH Proto-oncogene in Human Tumor Cell Lines. Exposure of Syrian hamster embryo fibroblasts to chemical carcinogens resulted in the oncogenic activation of the PCPH proto-oncogene by induction of a single base-pair deletion that generated a truncated PCPH oncoprotein (mutated PCPH). Recently, we isolated and characterized the cDNA for the human PCPH proto-oncogene and determined that in humans PCPH is a single-copy gene located in chromosome 14 (14q24.3). Pilot mRNA expression studies indicated that PCPH was expressed in the majority of normal organs tested, particularly in liver and kidney, but it appeared to be expressed either at low levels or not at all in tumor cells or cell lines derived from the high-expressing tissues. We have generated an antiserum against bacterial recombinant Syrian hamster PCPH. This antiserum recognizes both the normal and truncated, oncogenic Syrian hamster PCPH proteins and cross-reacts with the yeast, mouse, rat and human homologue proteins. Using this antibody, we have performed a study of PCPH expression in a larger sample of human neoplastic cell lines, including some derived from breast, nervous system, colon, lung and pancreas tumors. Results confirmed the frequent lack of PCPH expression in malignant cells and identified several immunoreactive forms of PCPH being differentially expressed in cells of diverse tissue origins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11121232     DOI: 10.1667/0033-7587(2001)155[0181:eotppo]2.0.co;2

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  6 in total

1.  Truncation of histone H2A's C-terminal tail, as is typical for Ni(II)-assisted specific peptide bond hydrolysis, has gene expression altering effects.

Authors:  Aldona A Karaczyn; Robert Y S Cheng; Gregory S Buzard; James Hartley; Dominic Esposito; Kazimierz S Kasprzak
Journal:  Ann Clin Lab Sci       Date:  2009       Impact factor: 1.256

2.  Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors.

Authors:  Michal Mikula; Tymon Rubel; Jakub Karczmarski; Krzysztof Goryca; Michal Dadlez; Jerzy Ostrowski
Journal:  Funct Integr Genomics       Date:  2010-11-09       Impact factor: 3.410

3.  PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.

Authors:  Joaquín Villar; Humair S Quadri; Insun Song; York Tomita; Oscar M Tirado; Vicente Notario
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

Review 4.  NTPDase5/PCPH as a new target in highly aggressive tumors: a systematic review.

Authors:  Paula Andreghetto Bracco; Ana Paula Santin Bertoni; Márcia Rosângela Wink
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

5.  ENTPD5: identification of splicing variants and their impact on cancer survival.

Authors:  Rafael Paschoal de Campos; Marcia Rosângela Wink; Guido Lenz
Journal:  Purinergic Signal       Date:  2021-06-02       Impact factor: 3.765

6.  The ENTPD5/mt-PCPH oncoprotein is a catalytically inactive member of the ectonucleoside triphosphate diphosphohydrolase family.

Authors:  Caitlin M MacCarthy; Vicente Notario
Journal:  Int J Oncol       Date:  2013-08-06       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.